Evidence map›Paper›PMID 41784728›Full record

SynthesisClinical and experimental medicine2026

Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials.

Fatemeh Shakibaei, Sepehr Malekshahi, Nazila Heidari, Amirhossein Heidari

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fatemeh Shakibaei *School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.ORCID http://orcid.org/0009-0007-7851-6313
Sepehr Malekshahi *School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.ORCID http://orcid.org/0009-0006-6521-946X
Nazila HeidariSchool of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-7259-4926
Amirhossein HeidariFaculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. amirhosseinheidari.md@gmail.com.ORCID http://orcid.org/0000-0003-4327-8814

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Denosumab biosimilars were developed to provide cost-effective alternatives to the reference monoclonal antibody for postmenopausal osteoporosis (PMO). This review assessed their efficacy, safety, and immunogenicity in the treatment of PMO. A systematic search of PubMed/Medline, Ovid-Embase, and Web of Science (to April 2025) identified randomized controlled trials comparing denosumab biosimilars with either the originator (Prolia

Indexed as

Biosimilar PharmaceuticalsBone Density Conservation AgentsDenosumabOsteoporosis, PostmenopausalBone DensityFemaleHumansRandomized Controlled Trials as TopicTreatment OutcomeBiosimilar PharmaceuticalsBone Density Conservation AgentsDenosumabBone mineral densityDenosumabDenosumab biosimilarPostmenopausal osteoporosisSystematic review

Identifiers

PMID41784728
PMCPMC12979263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.